Jpmorgan Chase & CO Procept Bio Robotics Corp Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 896,747 shares of PRCT stock, worth $87 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
896,747
Previous 73,189
1125.25%
Holding current value
$87 Million
Previous $3.62 Million
1414.57%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding PRCT
# of Institutions
224Shares Held
36.3MCall Options Held
251KPut Options Held
101K-
Vanguard Group Inc Valley Forge, PA4.71MShares$457 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.49MShares$338 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY1.81MShares$176 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.75MShares$170 Million0.07% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.37MShares$133 Million0.53% of portfolio
About PROCEPT BioRobotics Corp
- Ticker PRCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 44,592,300
- Market Cap $4.33B
- Description
- PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...